Twenty years post‐NIH Revitalization Act: Enhancing minority participation in clinical trials (EMPaCT): Laying the groundwork for improving minority clinical trial accrual

The National Institutes of Health (NIH) Revitalization Act of 1993 mandated the appropriate inclusion of minorities in all NIH‐funded research. Twenty years after this act, the proportion of minority patients enrolled in cancer clinical trials remains persistently low. Clinical trials are vehicles for the development and evaluation of therapeutic and preventive agents under scientifically rigorous conditions. Without representation in trials, it is projected that disparities in the cancer burden for minorities will increase.

[1]  C. Mazure,et al.  The inclusion of women and minorities in smoking cessation clinical trials: a systematic review. , 2009, The American journal on addictions.

[2]  W. McCaskill-Stevens,et al.  Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[4]  D. Ransohoff,et al.  Interpretations of 'appropriate' minority inclusion in clinical research. , 2004, The American journal of medicine.

[5]  Shari Bolen,et al.  Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic review , 2008, Cancer.

[6]  Karl Atkin,et al.  Why ethnic minority groups are under-represented in clinical trials: a review of the literature. , 2004, Health & social care in the community.

[7]  L. Siminoff,et al.  Barriers to therapeutic clinical trials enrollment: Differences between African-American and white cancer patients identified at the time of eligibility assessment , 2012, Clinical trials.

[8]  A. Moyer,et al.  Predictors of awareness of clinical trials and feelings about the use of medical information for research in a nationally representative US sample , 2010, Ethnicity & health.

[9]  E. Arias,et al.  Deaths: final data for 2000. , 2002, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.

[10]  Taylor J. Maxwell,et al.  Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes , 2008, Clinical Cancer Research.

[11]  Aisha T. Langford,et al.  Clinical Trial Awareness Among Racial/Ethnic Minorities in HINTS 2007: Sociodemographic, Attitudinal, and Knowledge Correlates , 2010, Journal of health communication.

[12]  Harlan M Krumholz,et al.  Participation in cancer clinical trials: race-, sex-, and age-based disparities. , 2004, JAMA.

[13]  E. Emanuel,et al.  Are Racial and Ethnic Minorities Less Willing to Participate in Health Research? , 2005, PLoS medicine.

[14]  R. Pietrobon,et al.  Gender, Racial, and Ethnic Disclosure in NIH K-Award Funded Diabetes and Obesity Clinical Trials , 2006, Accountability in research.

[15]  S. Geller,et al.  Inclusion, analysis, and reporting of sex and race/ethnicity in clinical trials: have we made progress? , 2011, Journal of women's health.

[16]  J. Grisso,et al.  Evaluating minority recruitment into clinical studies: how good are the data? , 1997, Annals of epidemiology.

[17]  W. McCaskill-Stevens,et al.  Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial , 2010, Clinical trials.

[18]  J. Whelan,et al.  Recruitment of adolescents and young adults to cancer clinical trials--international comparisons, barriers, and implications. , 2010, Seminars in oncology.

[19]  J. Kestle.  Clinical Trials , 2014, World Journal of Surgery.

[20]  J. Cuzick,et al.  CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. , 2012, Journal of the National Cancer Institute.

[21]  P. Neven,et al.  CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. , 2012, Journal of the National Cancer Institute.

[22]  Malcolm A. Smith,et al.  Equal Participation of Minority Patients in U.S. National Pediatric Cancer Clinical Trials , 1997, Journal of pediatric hematology/oncology.

[23]  M. Simon,et al.  Predictors of enrollment in lung cancer clinical trials , 2006, Cancer.

[24]  Robert N. Anderson,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels , 2013, Journal of the National Cancer Institute.

[25]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[26]  H. Kuerer,et al.  Features Associated with Successful Recruitment of Diverse Patients onto Cancer Clinical Trials: Report from the American College of Surgeons Oncology Group , 2011, Annals of Surgical Oncology.

[27]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[28]  W. Al-Refaie,et al.  Does enrollment in cancer trials improve survival? , 2013, Journal of the American College of Surgeons.

[29]  Moon S. Chen,et al.  Overcoming barriers to cancer clinical trial accrual , 2008, Cancer.

[30]  Deepa Naishadham,et al.  Cancer statistics for Hispanics/Latinos, 2012 , 2012, CA: a cancer journal for clinicians.